Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | DRD5 | P21918 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275716 | 0.85 | OPRD1 (0.74) | OPRD1KCNH2OPRK1CYP2D6HTR2C | |
| SCHEMBL4950798 | 0.84 | OPRD1 (0.47) | OPRD1KCNH2OPRK1CYP2D6CNR2 | |
| Hydrochloric Acid SCHEMBL7175052 | 0.83 | OPRD1 (0.47) | OPRD1KCNH2OPRK1CYP2D6CNR2 | |
| SCHEMBL19289109 | 0.82 | OPRD1 (0.66) | OPRD1KCNH2OPRK1CYP2D6 | |
| SCHEMBL4281185 | 0.80 | OPRD1 (0.46) | OPRD1KCNH2OPRK1PTPN1KMT2A | |
| SCHEMBL471210 | 0.75 | OPRD1 (0.74) | OPRD1KCNH2OPRK1CYP2D6HTR2C | |
| SCHEMBL471212 | 0.73 | OPRD1 (0.45) | OPRD1KCNH2OPRK1CYP2D6KMT2A | |
| SCHEMBL13566251 | 0.71 | OPRD1 (0.56) | OPRD1KCNH2OPRK1CYP2D6TP53 | |
| Hydrochloric Acid SCHEMBL4276817 | 0.71 | OPRD1 (0.61) | OPRD1KCNH2OPRK1CYP2D6 | |
| SCHEMBL13005015 | 0.70 | HTR2C (0.70) | KCNH2DRD2DRD1DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507824-B2 | Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors | N.V. ORGANON (NL) | 2009-03-24 | — | — | US | disclosed |
| EP-1232160-B1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS | ORGANON NV (NL) | 2008-06-18 | — | — | EP | disclosed |
| US-20040029904-A1 | Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors | MERCK SHARP & DOHME B.V. (NL) | 2004-02-12 | — | — | US | disclosed |
| US-6645973-B1 | Heterocyclic amines such as 1-carboxymethyl-4-(4-chlorophenyl) spiro(2H-1-benzopyran-2,4'-piperidine)hydrochloride used for therapy of nervous system disorders; Alzheimer's, Parkinson's and Huntington's disease | AKZO NOBEL (NL) | 2003-11-11 | — | — | US | disclosed |
| EP-1232160-A1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS | Akzo Nobel N.V. (NL) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036423-A1 | SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE) DERIVATES AS GLYCINE TRANSPORT INHIBITORS | AKZO NOBEL N.V. (NL) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029904-A1 | Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors | SLC6A7, SLC1A2, SLC6A1 | OPRD1 504/4885KCNH2 277/4885OPRK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.